SUNLENCA

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Israel, Italy, Lithuania, Romania, UK.

Active ingredients

The drug SUNLENCA contains one active pharmaceutical ingredient (API):

1	Lenacapavir UNII A9A0O6FB4H - LENACAPAVIR
	Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid protein (CA) subunits. Lenacapavir inhibits HIV-1 replication by interfering with multiple, essential steps of the viral lifecycle, including capsid-mediated nuclear uptake of HIV-1 proviral DNA, virus assembly and release, and capsid core formation.
	Read more about Lenacapavir

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SUNLENCA Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)
SUNLENCA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AX31		J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AX Other antivirals
Discover more medicines within J05AX31

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3036721, 3044854
FR	Base de données publique des médicaments	62721516, 65950064
IL	מִשְׂרַד הַבְּרִיאוּת	9251, 9252
IT	Agenzia del Farmaco	050232014, 050232026
LT	Valstybinė vaistų kontrolės tarnyba	1095364, 1095365
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69101001, W69102001